Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Re: cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma: B. A. Gayed, C. Seideman and y. Lotan J Urol 2013;190:1181-1186.

Tian Y, Wazir R, Wang K.

J Urol. 2014 May;191(5):1472. doi: 10.1016/j.juro.2013.11.050. Epub 2014 Feb 7. No abstract available.

PMID:
24513143
[PubMed - indexed for MEDLINE]
2.

Cost-effectiveness of fluorescence in situ hybridization in patients with atypical cytology for the detection of urothelial carcinoma.

Gayed BA, Seideman C, Lotan Y.

J Urol. 2013 Oct;190(4):1181-6. doi: 10.1016/j.juro.2013.03.117. Epub 2013 Apr 9.

PMID:
23583531
[PubMed - indexed for MEDLINE]
3.

Reply by authors.

[No authors listed]

J Urol. 2014 May;191(5):1472-3. doi: 10.1016/j.juro.2013.11.118. Epub 2014 Feb 7. No abstract available.

PMID:
24513142
[PubMed - indexed for MEDLINE]
4.

What is the role of cost-effectiveness analysis in clinical practice?

Erickson BA.

J Urol. 2013 Oct;190(4):1163-4. doi: 10.1016/j.juro.2013.07.024. Epub 2013 Jul 18. No abstract available.

PMID:
23871931
[PubMed - indexed for MEDLINE]
5.

Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R.

J Urol. 2008 Jun;179(6):2164-9. doi: 10.1016/j.juro.2008.01.105. Epub 2008 Apr 18.

PMID:
18423745
[PubMed - indexed for MEDLINE]
6.

Prospective validation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.

Schlomer BJ, Ho R, Sagalowsky A, Ashfaq R, Lotan Y.

J Urol. 2010 Jan;183(1):62-7. doi: 10.1016/j.juro.2009.08.157. Epub .

PMID:
19913822
[PubMed - indexed for MEDLINE]
7.

Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma.

Veeramachaneni R, Nordberg ML, Shi R, Herrera GA, Turbat-Herrera EA.

Diagn Cytopathol. 2003 Jun;28(6):301-7.

PMID:
12768634
[PubMed - indexed for MEDLINE]
8.

Fluorescence in situ hybridization in the diagnosis of urothelial carcinoma.

Bubendorf L.

Ann Pathol. 2010 Nov;30(5 Suppl 1):117-8. doi: 10.1016/j.annpat.2010.07.024. Epub 2010 Sep 15. No abstract available.

PMID:
21055567
[PubMed - indexed for MEDLINE]
9.

9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology.

Kawauchi S, Sakai H, Ikemoto K, Eguchi S, Nakao M, Takihara H, Shimabukuro T, Furuya T, Oga A, Matsuyama H, Takahashi M, Sasaki K.

Hum Pathol. 2009 Dec;40(12):1783-9. doi: 10.1016/j.humpath.2009.06.011. Epub 2009 Sep 5.

PMID:
19733894
[PubMed - indexed for MEDLINE]
10.

The utility of fluorescence in situ hybridization for detection of bladder urothelial carcinoma in routine clinical practice.

Kwak KW, Kim SH, Lee HM.

J Korean Med Sci. 2009 Dec;24(6):1139-44. doi: 10.3346/jkms.2009.24.6.1139. Epub 2009 Nov 9.

PMID:
19949672
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

[Cytology of the urinary tract: Between uncertainty and clarity].

Bubendorf L, Dalquen P, Savic S.

Pathologe. 2009 Dec;30 Suppl 2:173-8. doi: 10.1007/s00292-009-1190-8. Review. German.

PMID:
19820939
[PubMed - indexed for MEDLINE]
12.

[Detection of urothelial carcinoma of the urinary bladder by multicolor fluorescence in situ hybridization].

Zhang YG, Bi XG, Han YL, Cai Y, Xu X, Wu YP, Yang YL, Ma JH, Zhao P, Jia XM, Wang MR.

Ai Zheng. 2007 Feb;26(2):189-93. Chinese.

PMID:
17298751
[PubMed - indexed for MEDLINE]
13.

[FISH and thin layer in urinary cytology].

Paglierani M, Castiglione F, Garbini F, Buccoliero AM, Raspollini MR, Lapini A, Vignolini G, Taddei GL.

Pathologica. 2005 Aug;97(4):200. Italian. No abstract available.

PMID:
16440661
[PubMed - indexed for MEDLINE]
14.

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.

Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, Procop GW, Jones JS, Ulchaker J, Zippe CD, Tubbs RR.

J Urol. 2003 Jun;169(6):2101-5.

PMID:
12771727
[PubMed - indexed for MEDLINE]
15.

Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder.

Degtyar P, Neulander E, Zirkin H, Yusim I, Douvdevani A, Mermershtain W, Kaneti J, Manor E.

Urology. 2004 Feb;63(2):398-401.

PMID:
14972510
[PubMed - indexed for MEDLINE]
16.

Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.

May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lübbe L, Nowack R, Siegsmund M, Hoschke B.

Urology. 2007 Sep;70(3):449-53. Epub 2007 Aug 3.

PMID:
17688921
[PubMed - indexed for MEDLINE]
17.

Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance.

Johannes JR, Nelson E, Bibbo M, Bagley DH.

J Urol. 2010 Sep;184(3):879-82. doi: 10.1016/j.juro.2010.05.023.

PMID:
20643443
[PubMed - indexed for MEDLINE]
18.

Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples.

Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y, Friberger A, Kidron D, Kaplan E, Lew S, Leibovitch I.

Urology. 2005 Dec;66(6):1354-9.

PMID:
16360483
[PubMed - indexed for MEDLINE]
19.

Re: Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. M. K. Tollefson, M. L. Blute, S. A. Farmer and I. Frank J Urol 2010; 183: 81-86.

Huang YH.

J Urol. 2010 Sep;184(3):1222-3; author reply 1223. doi: 10.1016/j.juro.2010.05.011. Epub 2010 Jul 24. No abstract available.

PMID:
20655549
[PubMed - indexed for MEDLINE]
20.

Impact of second opinion pathology in the definitive management of patients with bladder carcinoma.

Coblentz TR, Mills SE, Theodorescu D.

Cancer. 2001 Apr 1;91(7):1284-90.

PMID:
11283928
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk